Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Esperite (voorheen Cryo Save) Terug naar discussie overzicht

Gerelateerd nieuws

98 Posts
Pagina: «« 1 2 3 4 5 | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 25 juni 2018 15:13
    quote:

    Snaarwegger schreef op 25 juni 2018 15:09:

    [...]In dat geval stel ik voor... : makkelijke vragen.
    Probeer het eens zou ik zeggen; ik heb geen vragen voor Amar en jij moet nog een hoop leren.
  2. [verwijderd] 25 juni 2018 15:16
    quote:

    DeZwarteRidder schreef op 25 juni 2018 15:13:

    [...]
    Probeer het eens zou ik zeggen; ik heb geen vragen voor Amar en jij moet nog een hoop leren.
    Ik heb nieuws voor je, ik moet helemaal niks.

    Alhoewel... ik moet nu weg...
  3. forum rang 4 bik 25 juni 2018 15:26
    Ai jammer.Bent U de enige hier die af en toe moet werken? De rest loopt hier binnen op koerswinst uiteraard. Grrr.
  4. VolvoR 26 juni 2018 15:30
    quote:

    bik schreef op 25 juni 2018 15:26:

    Ai jammer.Bent U de enige hier die af en toe moet werken? De rest loopt hier binnen op koerswinst uiteraard. Grrr.
    Nee, ik ben net klaar met werken, zou ook liever stoppen maar dat gaat nog lang niet.Onze ridder is ook al te vinden op het Gaussin forum, heeft blijkbaar direct verstand van deze mooie electrische wagentjes en weet ook alles over deze markt.Raar, ik kom hem nooit tegen in die Quote 500 lijst.
  5. [verwijderd] 27 juni 2018 12:01
    quote:

    VolvoR schreef op 26 juni 2018 15:30:

    [...]

    Nee, ik ben net klaar met werken, zou ook liever stoppen maar dat gaat nog lang niet.Onze ridder is ook al te vinden op het Gaussin forum, heeft blijkbaar direct verstand van deze mooie electrische wagentjes en weet ook alles over deze markt.Raar, ik kom hem nooit tegen in die Quote 500 lijst.
    Hij wil graag laten weten dat hij geen 'newbie' is en meer weet dan anderen
  6. [verwijderd] 19 juli 2018 15:05
    hitechreporter.com/global-stem-cell-b...

    The study also provides you with profiles of the companies, product pictures, their specifications, overall revenue, market share, size and contact details of the key manufacturers of 2018-2025 Stem Cell Banking Report on Global , some of them listed here are China Cord Blood Corporation, CBR Systems, Inc., Esperite, Vcanbio, Boyalife Group, LifeCell.
  7. forum rang 10 DeZwarteRidder 19 juli 2018 15:09
    quote:

    Snaarwegger schreef op 19 juli 2018 15:05:

    The study also provides you with profiles of the companies, product pictures, their specifications, overall revenue, market share, size and contact details of the key manufacturers of 2018-2025 Stem Cell Banking Report on Global , some of them listed here are China Cord Blood Corporation, CBR Systems, Inc., Esperite, Vcanbio, Boyalife Group, LifeCell.
  8. [verwijderd] 24 augustus 2018 10:50
    The Cell Factory is currently developing EV's biologic drugs for:

    - CF-MEV-107 for Crohn's disease (drug-resistant perianal fistulae)

    The Cell Factory is leading a translational project on EV's first in man use in treatment of Crohn's disease perianal fistulas. Inflammatory bowel disease (IBD) encompasses a spectrum of diseases affecting gastrointestinal tract. The most common are Crohn's disease and ulcerative colitis. IBD is a chronic and often recurring inflammation of the intestines with unknown cause and limited treatment options. In the most severe cases of Crohn's disease, the patients suffer from perianal fistulas that significantly affect normal activity and may lead to complications such an increased risk of cancer and life-threating systemic inflammation.

    Epidemiology and market estimation: IBD affects approximately 0.5% of the western countries population and this number is rapidly increasing. There are over 0.5 million people in the US and over 1 million in Europe with Crohn's disease, with over 10 new cases per 100.000 people every year. The annual cost of therapy exceeds 5 billion USD in the US only (CDC). Up to 50% of Crohn's disease patients are affected with difficult to treat perianal fistulas, and 75% require surgery (according to CDC) what estimates the potential market size of the CF-MEV-107.

    - CF-MEV-117 for Epilepsy (acute and chronic drug-resistant epilepsy)

    The Cell Factory is developing MSC-EV's drug candidate for treatment of untreatable-yet acute and chronic drug-resistant epilepsy. Epilepsy carries significant detrimental effects on the quality of life and can lead to a secondary brain damage. The disease can have different etiology, including stroke, brain trauma, and neuro-inflammation.

    Epidemiology and market estimation: Epilepsy is one of the most common brain diseases affecting about 1 in 100 children under 17-year old according to CDC. Severity of the seizures is variable and the antiepileptic drugs are effective only in about 2/3 of the patients. CDC estimated annual costs related to epilepsy exceed 15 billion USD in the United States alone.

    - CF-MEV-126 for stroke (brain stroke and acute injuries of central nervous system)

    Brain stroke is the most devastating neurological disease with no effective therapy available yet. The brain damage could be significantly reduced if anti-inflammatory and neuroprotecting treatment is applies immediately after stroke or injury. Esperite is looking for partners to support the development of extracellular vesicle therapeutics.

    Epidemiology and market estimation: According to WHO, 1 in 6 people will have a stroke during lifetime and 6 million people die because of stroke every year. Those who survive, very often suffer from severe physical and cognitive impairments due to brain damage following stroke. CDC estimates the brain stroke related costs on 34 billion USD every year only in the United States.

    About the partners:

    The department of Woman's and Child's Heath of the University of Padua is tertiary paediatric academic care centre, serving the entire North East region of Italy, devoted to provide excellence in patient's care, teaching and research, also including a ten-store research building. It is one of the eleven fully recognised Italian Children's Hospitals.

    ESPERITE Group (Euronext: ESP), listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

    The Cell Factory is a company of ESPERITE Group, focused on innovative drug products development, clinical translation and commercialization using autologous mesenchymal stromal cells (MSCs) and allogenic MSC-derived extracellular vesicles (MSC-EV's). TCF-Biotech goal is a development of the highest quality therapeutic tools for affordable treatment of unmet medical needs.

    To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 - ir@esperite.com or visit the website at www.esperite.com
  9. forum rang 8 aextracker 24 augustus 2018 11:48
    Volgens het laatste persbericht volgt voor eind volgende week nadere informative over de timing van oplevering\vrijgave JV 2017.

    Blijkbaar zijn er nog hoopvolle spelers in het veld, die de voorzetjes weten in te koppen.

    Immers wie speelt kan scoren, de toeschouwers kunnen slechts hopen dat de spelers hen horen :)
98 Posts
Pagina: «« 1 2 3 4 5 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.910
AB InBev 2 5.352
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.581 49.589
ABO-Group 1 21
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 262
Accsys Technologies 22 9.621
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 173
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 13 17.419
Aedifica 3 885
Aegon 3.257 321.614
AFC Ajax 537 7.051
Affimed NV 2 6.059
ageas 5.843 109.832
Agfa-Gevaert 13 1.949
Ahold 3.536 74.137
Air France - KLM 1.024 34.639
AIRBUS 1 10
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.902
Alfen 15 21.686
Allfunds Group 3 1.303
Almunda Professionals (vh Novisource) 651 4.250
Alpha Pro Tech 1 17
Alphabet Inc. 1 367
Altice 106 51.197
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.791
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.824 241.071
AMG 965 130.496
AMS 3 73
Amsterdam Commodities 303 6.599
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 414
Antonov 22.632 153.605
Aperam 91 14.521
Apollo Alternative Assets 1 17
Apple 5 357
Arcadis 251 8.663
Arcelor Mittal 2.028 319.692
Archos 1 1
Arcona Property Fund 1 278
arGEN-X 15 9.698
Aroundtown SA 1 210
Arrowhead Research 5 9.462
Ascencio 1 24
ASIT biotech 2 697
ASMI 4.107 38.308
ASML 1.763 89.635
ASR Nederland 19 4.378
ATAI Life Sciences 1 7
Atenor Group 1 373
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 31 11.917
Axsome Therapeutics 1 177
Azelis Group 1 59
Azerion 7 2.866

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 19 september

    1. Werkloosheid augustus (NL)
    2. Turkse centrale bank rentebesluit
    3. Bank of England rentebesluit (VK) 5% (onveranderd) volitaliteit verwacht
    4. Steunaanvragen - wekelijks (VS)
    5. Philadelphia Fed index september (VS)
    6. Bestaande woningverkopen augustus (VS)
    7. Consumentenvertrouwen (UvM) aug (VS)
    8. FedEx cijfers eerste kwartaal
  2. 20 september

    1. Inflatie augustus (Japan) volitaliteit verwacht
    2. Rentebesluit Bank of Japan volitaliteit verwacht
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht